Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cefetamet. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.78 |
| ▸ | PPARG known ✓ | P37231 | 2/20 | 0.75 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.73 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.71 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.64 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.64 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.64 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.75 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.75 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.75 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.75 |
| ▸ | ALB | P02768 | 1/20 | 0.75 |
| ▸ | PGR | P06401 | 3/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.66 |
| ▸ | APEX1 | P27695 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.66 |
| ▸ | APAF1 | O14727 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefetamet SCHEMBL2586142 | 1.00 | NR1I2 (0.78) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL11211852 | 1.00 | NR1I2 (0.78) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL11211861 | 1.00 | NR1I2 (0.78) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL27791862 | 0.99 | NR1I2 (0.77) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL65620 | 0.99 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL9367206 | 0.99 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL7863727 | 0.99 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL10587831 | 0.99 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL10587826 | 0.99 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 | |
| Cefetamet SCHEMBL151099 | 0.99 | NR1I2 (0.79) | NR1I2HTR2CMAPTPPARGSLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119470736-B | Method for improving quality control of cefditoren pivoxil particles | 广州艾奇西医药科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119470736-A | Method for improving quality control of cefditoren pivoxil particles | 广州艾奇西医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-114728093-B | Wound dressing for hemostasis and wound healing and preparation method thereof | 株式会社MEDITIP | 2023-04-28 | — | — | CN | disclosed |
| CN-113801141-B | Preparation method of cefetamet pivoxil hydrochloride | 成都倍特药业股份有限公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-113081991-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-109431965-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-113801141-A | Preparation method of cefetamet pivoxil hydrochloride | 成都倍特药业股份有限公司 | 2021-12-17 | — | — | CN | disclosed |
| CN-108653221-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-113171350-A | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2021-07-27 | — | — | CN | disclosed |
| CN-113133980-A | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2021-07-20 | — | — | CN | disclosed |
| CN-106236715-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-108721242-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2021-03-02 | — | — | CN | disclosed |
| EP-2566450-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CEFETAMET | Bilgic, Mahmut (TR) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011139255-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CEFETAMET | BILGIC MAHMUT (TR) | 2011-11-10 | — | — | WO | disclosed |
| CN-1303086-C | Compound of dual functional esterified prodrug of Cefetamet, and oral preparation | ZHU XIAOMAO (CN) | 2007-03-07 | — | — | CN | disclosed |
| CN-1650868-A | Compound medicinal preparation for treating pneumonia infection disease and its preparation method | SICHUAN CHUANTOU MEDICINE BIOT (CN) | 2005-08-10 | — | — | CN | disclosed |
| CN-1208060-C | Compound of ceferamet used for injection | HE GUANGWEI (CN) | 2005-06-29 | — | — | CN | disclosed |
| CN-1600313-A | Cefetamet pivoxil hydrochloride dispersion dispersion tablets and preparation method | DONGBEI PHARMACEUTICAL MFG PLA (CN) | 2005-03-30 | — | — | CN | disclosed |
| CN-1430961-A | Compound of ceferamet used for injection | HE GUANGWEI (CN) | 2003-07-23 | — | — | CN | disclosed |
| US-5359057-A | Reacting 6-aminopenicillin derivative in the form of an acid addition salt with 2-benzothiazolyl thioester derivative to form amide of penecillin or cephalosporin derivatives; microbiocides | HOFFMANN-LA ROCHE INC. (US) | 1994-10-25 | — | — | US | disclosed |